Kite Announces Two-Year Data for Yescarta (Axicabtagene Ciloleucel)...


Dec 2, 2018--Kite, a Gilead Company , announced two-year efficacy and safety data from the pivotal ZUMA-1 trial of Yescarta A in patients with refractory large B-cell lymphoma. With a minimum follow-up of two years after a single infusion of Yescarta , 39 percent of patients were in an ongoing response.



from Biotech News